Our findings, that a reduction of inflammation via IL-6R blockade in hospitalized patients with COVID-19 only minimally increased HDL-C levels, suggests that the HDL-C depression observed during acute infection is not linked to the IL-6R–mediated inflammatory state but rather reflects engagement of HDL-C in the immune response, as has been suggested for other viral infections (3). Here, IL6R is linked to COVID-19.